- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cost Prevents Approval of Revlimid in the UK...Again
NICE rejected Celgene's Revlimid again for treating patients with myelodysplastic syndrome, quoting concerns with cost-effectiveness of the drug.
Patients with a specific type of bone marrow disorder in England and Wales will be disappointed by news that cost regulators have not approved National Health Service use of Celgene's Revlimid (lenalidomide).
In draft guidance published this week, the National Institute for Health and Care Excellence (NICE) has turned down funding for the drug in patients with myelodysplastic syndromes characterised by a a certain chromosomal abnormality called a deletion 5q cytogenetic abnormality.
This is because while clinical experts told the committee that Revlimid is an effective therapy, the data provided by Celgene "showed uncertainty about whether lenalidomide actually extended lives", the Institute said, although it's Committee did concede that a survival benefit was plausible.
Report: http://bit.ly/R8HxAF
Source: PharmaTimes online
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
